Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

First U.S. marketing approval for Cephalon: Provigil cleared for narcolepsy-associated EDS

Dec. 29, 1998

YM-872: neuroprotective effects in animal model indicate potential in acute ischemic stroke

Dec. 29, 1998

Peripheral nerve regeneration enhanced by hyaluronic acid in rat model

Dec. 29, 1998

More CRF antagonists emerge from Janssen/Neurocrine Biosciences collaboration

Dec. 29, 1998

Guilford patents NAALADase inhibitors for glutamate abnormalities, prostate conditions

Dec. 28, 1998

Revolutionary drugs for Alzheimer's ready for human testing described by Nymox

Dec. 28, 1998

Agents for epilepsy, stroke and brain, spinal cord trauma in development at Novartis

Dec. 28, 1998

Collaborative work by Janssen and Neurocrine Biosciences related to CRF antagonists

Dec. 28, 1998

New 5-HT4 and/or H3 receptor ligands designed at Synthelabo

Dec. 28, 1998

HSP-117: newly synthesized NK1 receptor antagonist with potent antiemetic effects

Dec. 23, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...